sumatriptan has been researched along with Abnormalities, Drug-Induced in 9 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review the literature for treatment of migraine headaches with sumatriptan during pregnancy." | 8.82 | Treatment of migraine headaches with sumatriptan in pregnancy. ( Cross, LB; Eichner, SF; Hilaire, ML, 2004) |
| "Assessment of best available evidence for tolerability of sumatriptan after inadvertent exposure during pregnancy." | 7.71 | Evidence-based assessment of pregnancy outcome after sumatriptan exposure. ( Anderson, PO; Chambers, CD; Diamond, ML; Fox, AW; Spierings, EL, 2002) |
| "To review the literature for treatment of migraine headaches with sumatriptan during pregnancy." | 4.82 | Treatment of migraine headaches with sumatriptan in pregnancy. ( Cross, LB; Eichner, SF; Hilaire, ML, 2004) |
| "Using the Marketscan database, the risk of major birth defects was ascertained in live-born infants whose birth mothers were exposed to sumatriptan, naratriptan, or sumatriptan/naproxen during pregnancy." | 3.88 | Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study. ( Bollinger, L; Cangialose, C; Chia, V; Mikol, DD; Xue, F; Yusuf, A, 2018) |
| "Assessment of best available evidence for tolerability of sumatriptan after inadvertent exposure during pregnancy." | 3.71 | Evidence-based assessment of pregnancy outcome after sumatriptan exposure. ( Anderson, PO; Chambers, CD; Diamond, ML; Fox, AW; Spierings, EL, 2002) |
| " The proportions of outcomes with birth defects are as follows: in the Acyclovir (antiviral medication) Pregnancy Registry (1984-1998) (19/581), 3." | 3.70 | Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. ( Andrews, EB; Ephross, SA; Heffner, CR; Reiff-Eldridge, R; Tennis, PS; White, AD, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yusuf, A | 1 |
| Chia, V | 1 |
| Xue, F | 1 |
| Mikol, DD | 1 |
| Bollinger, L | 1 |
| Cangialose, C | 1 |
| Bejan-Angoulvant, T | 1 |
| Beau-Salinas, F | 1 |
| Lengellé, C | 1 |
| Cissoko, H | 1 |
| Jonville-Béra, AP | 1 |
| Hultzsch, S | 1 |
| Schaefer, C | 1 |
| Fox, AW | 2 |
| Rousso, P | 1 |
| Hilaire, ML | 1 |
| Cross, LB | 1 |
| Eichner, SF | 1 |
| Reiff-Eldridge, R | 1 |
| Heffner, CR | 1 |
| Ephross, SA | 1 |
| Tennis, PS | 1 |
| White, AD | 1 |
| Andrews, EB | 1 |
| Chambers, CD | 1 |
| Anderson, PO | 1 |
| Diamond, ML | 1 |
| Spierings, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Sumatriptan and Naratriptan Pregnancy Registry[NCT01059604] | 868 participants (Actual) | Observational [Patient Registry] | 2001-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for sumatriptan and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Migraine and pregnancy. Choice of treatment.
Topics: Abnormalities, Drug-Induced; Female; Fetus; Gestational Age; Humans; Migraine Disorders; Patient Sel | 2014 |
[Analgesic drugs during pregnancy].
Topics: Abnormalities, Drug-Induced; Acetaminophen; Acute Pain; Analgesics; Analgesics, Opioid; Anticonvulsa | 2016 |
Treatment of migraine headaches with sumatriptan in pregnancy.
Topics: Abnormalities, Drug-Induced; Clinical Trials as Topic; Female; Humans; Migraine Disorders; Pregnancy | 2004 |
6 other studies available for sumatriptan and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.
Topics: Abnormalities, Drug-Induced; Administrative Claims, Healthcare; Adolescent; Adult; Databases, Factua | 2018 |
[Drugs news].
Topics: Abnormalities, Drug-Induced; Anti-Retroviral Agents; Azathioprine; Female; Humans; Infant, Newborn; | 2015 |
Revised estimates for probability of successful outcome of pregnancy after sumatriptan exposure.
Topics: Abnormalities, Drug-Induced; Female; Humans; Infant, Newborn; Migraine Disorders; Pregnancy; Pregnan | 2004 |
[Drug exposure during pregnancy: a differentiated approach].
Topics: Abnormalities, Drug-Induced; Abortion, Eugenic; Alcohol Drinking; Benzodiazepines; Drug Therapy; Fem | 2004 |
Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
Topics: Abnormalities, Drug-Induced; Acyclovir; Anticonvulsants; Antiviral Agents; Drug Industry; Epilepsy; | 2000 |
Evidence-based assessment of pregnancy outcome after sumatriptan exposure.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Evidence-Based Medicine; Female; Humans; Infant, | 2002 |